Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Phagenesis announces the publication

Phagenesis announces the publication of its recent randomised controlled trial confirming the benefits of Phagenyx®

Nestlé Health Science's partner Phagenesis, a pioneering leader in the treatment of dysphagia, has announced today the publication of its most recent randomised controlled trial (PHAST-TRAC) in the journal Lancet Neurology. The PHAST-TRAC results confirm that tracheostomised stroke patients with swallowing problems can benefit from treatment with Pharyngeal Electrical Stimulation (PES), a novel therapy based on ground-breaking research. The Phagenyx® system developed by Phagenesis, is an innovative medical device that uses PES to restore the neurological control of swallowing in patients with post-stroke dysphagia.

Please view the full release on the Phagenesis website: http://www.phagenesis.com/general/2194